摘要
本研究旨在检测骨髓增生异常综合征(MDS)患者血浆DNA中FHIT基因启动子区域甲基化状况及地西他滨对其甲基化的影响。采用甲基化特异性聚合酶链反应法检测1例初治的MDS患者、3例MDS转化而来的AML患者在地西他滨序贯半量CAG方案化疗前后血浆DNA中FHIT基因启动子区域CPG岛甲基化情况,并分析其临床疗效。结果表明,3例患者治疗前有FHIT基因甲基化。治疗1个疗程后其中2例患者FHIT基因甲基化得到逆转,4例患者中有2例获得临床缓解,2例无效。结论:MDS的发生可能与FHIT基因甲基化相关,地西他滨对MDS患者血浆DNA中FHIT基因高甲基化具有明显的去甲基化作用。血浆DNA的FHIT基因甲基化检测可能成为MDS辅助诊断和预后判断的分子标记。
This study was aimed to detect the methylation status of FHIT gene promoter region in the DNA from plasma of patients with myelodysplastic syndrome（MDS）,and to investigate the demethylating effect of decitabine.Methylation-specific PCR method was used to detect the methylation status of FHIT gene promoter region in the DNA from plasma of 4 patients with MDS before and after treatment with decitabine plus semis CAG therapy（among them,1 case of newly diagnosed MDS,3 cases progressed into acute leukemia）.The results indicated that 3 cases were found to have an increased methylation in the promoter region.After treatment with decitabine plus semis CAG,increased methylation was reversed in 2 cases.In 4 cases,2 cases displayed clinical response.It is concluded that FHIT gene hypermethylation is associated with MDS pathogenesis.Decitabine has demethylating effect on the FHIT gene hypermethylation of plasma from MDS patients.Detecting the methylation status of FHIT gene in DNA from plasma may play a role in MDS auxiliary diagnosis or prognosis.
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2012年第5期1144-1148,共5页
Journal of Experimental Hematology
